BMS-986226 + ipilimumab

BMS-986226 + ipilimumab is a combination investigational immunotherapy regimen under clinical evaluation for advanced solid tumors. - **BMS-986226** is an experimental immunotherapy agent being developed by Bristol Myers Squibb; its precise molecular target and mechanism are not disclosed in public sources, but it is administered intravenously, typically in combination with immune checkpoint inhibitors[1][5]. - **Ipilimumab** (brand name: Yervoy, code: BMS-734016) is a monoclonal antibody and immune checkpoint inhibitor targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), promoting T-cell activation[1]. - This combination is being studied for its safety, tolerability, pharmacokinetic profile, immunogenicity, and preliminary anti-tumor activity in patients with advanced/metastatic, unresectable malignancies who have progressed on prior therapies[1][5]. - Developed by Bristol Myers Squibb, the combination is not approved for marketing but has reached Phase 1/2 clinical trial status for solid tumors[1][5].

Other names

BMS-986226 + ipilimumab